期刊
ONCOLOGIST
卷 15, 期 4, 页码 360-371出版社
ALPHAMED PRESS
DOI: 10.1634/theoncologist.2009-S104
关键词
Radioprotector; Mitigators; Amifostine; Tempol
类别
资金
- Center for Cancer Research, National Cancer Institute, National Institutes of Health
- Division of Intramural Research, National Institute of Dental and Craniofacial Research
- NATIONAL CANCER INSTITUTE [ZIASC006321, ZIASC006387, ZIABC010850, ZIABC010787] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [ZIADE000336] Funding Source: NIH RePORTER
Radiation is used in the treatment of a broad range of malignancies. Exposure of normal tissue to radiation may result in both acute and chronic toxicities that can result in an inability to deliver the intended therapy, a range of symptoms, and a decrease in quality of life. Radioprotectors are compounds that are designed to reduce the damage in normal tissues caused by radiation. These compounds are often antioxidants and must be present be-fore or at the time of radiation for effectiveness. Other agents, termed mitigators, may be used to minimize toxicity even after radiation has been delivered. Herein, we review agents in clinical use or in development as radioprotectors and mitigators of radiation-induced normal tissue injury. Few agents are approved for clinical use, but many new compounds show promising results in preclinical testing. The Oncologist 2010; 15: 360-371
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据